News & events Upcoming events Jun 1, 2023 - Jun 3, 2023 SEIMC 2023 - Congreso Nacional de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica Santiago de Compostela, Spain More info and meet us there Jun 1, 2023 - Jun 3, 2023 VII Conferencia Málaga Alzheimer Málaga, Spain More info and meet us there Jun 6, 2023 - Jun 9, 2023 Diagnostic pathways and management of sexually transmitted infections Bertinoro, Italy More info and meet us there See all upcoming events Latest news Mar 31, 2023 Fujirebio further extends its fully automated blood-based biomarker portfolio with the fully automated Lumipulse® G ApoE4 and Lumipulse® G Pan-ApoE assays for Research Use Only H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G ApoE4 and Lumipulse G... Read more Mar 28, 2023 Fujirebio expands its assay menu in the field of neurodegenerative diseases with the launch of the fully automated Lumipulse® G NfL CSF and Lumipulse® G NfL Blood tests Gent, Belgium, Malvern PA, USA, and Tokyo, Japan, March 28, 2023 – H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today... Read more Mar 8, 2023 AriBio Co., Ltd. and Fujirebio Diagnostics, Inc. announce strategic partnership to advance biomarker development for Alzheimer’s disease and neurodegeneration San Diego, CA and Tokyo, Japan and Malvern, PA – March 8, 2023 – Fujirebio Holdings Inc., its wholly-owned subsidiary Fujirebio Diagnostics... Read more Nov 7, 2022 Fujirebio acquires Fluxus to accelerate new platform development based on ultra-high sensitivity detection technology H.U. Group Holding Inc., and its wholly-owned subsidiary, Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa; Head Office: Shinjuku-ku... Read more Oct 11, 2022 Fujirebio Europe receives distribution rights to market Self-screen's PreCursor-M+ methylation-specific molecular assay, a powerful solution to identify women at high risk for cervical cancer Gent, Belgium and Amsterdam, The Netherlands – October 11, 2022: Fujirebio Europe and Self-screen B.V. today announce a commercial... Read more Jun 23, 2022 Fujirebio acquires ADx NeuroSciences and confirms its intentions to bring better and earlier neurodegenerative disease diagnostic solutions to the global diagnostics industry Gent, Belgium and Tokyo, Japan, June 23, 2022 – H.U. Group Holdings Inc., and its wholly-owned subsidiary Fujirebio Holdings, Inc., and ADx... Read more Load More
Jun 1, 2023 - Jun 3, 2023 SEIMC 2023 - Congreso Nacional de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica Santiago de Compostela, Spain More info and meet us there
Jun 6, 2023 - Jun 9, 2023 Diagnostic pathways and management of sexually transmitted infections Bertinoro, Italy More info and meet us there
Mar 31, 2023 Fujirebio further extends its fully automated blood-based biomarker portfolio with the fully automated Lumipulse® G ApoE4 and Lumipulse® G Pan-ApoE assays for Research Use Only H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G ApoE4 and Lumipulse G... Read more
Mar 28, 2023 Fujirebio expands its assay menu in the field of neurodegenerative diseases with the launch of the fully automated Lumipulse® G NfL CSF and Lumipulse® G NfL Blood tests Gent, Belgium, Malvern PA, USA, and Tokyo, Japan, March 28, 2023 – H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today... Read more
Mar 8, 2023 AriBio Co., Ltd. and Fujirebio Diagnostics, Inc. announce strategic partnership to advance biomarker development for Alzheimer’s disease and neurodegeneration San Diego, CA and Tokyo, Japan and Malvern, PA – March 8, 2023 – Fujirebio Holdings Inc., its wholly-owned subsidiary Fujirebio Diagnostics... Read more
Nov 7, 2022 Fujirebio acquires Fluxus to accelerate new platform development based on ultra-high sensitivity detection technology H.U. Group Holding Inc., and its wholly-owned subsidiary, Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa; Head Office: Shinjuku-ku... Read more
Oct 11, 2022 Fujirebio Europe receives distribution rights to market Self-screen's PreCursor-M+ methylation-specific molecular assay, a powerful solution to identify women at high risk for cervical cancer Gent, Belgium and Amsterdam, The Netherlands – October 11, 2022: Fujirebio Europe and Self-screen B.V. today announce a commercial... Read more
Jun 23, 2022 Fujirebio acquires ADx NeuroSciences and confirms its intentions to bring better and earlier neurodegenerative disease diagnostic solutions to the global diagnostics industry Gent, Belgium and Tokyo, Japan, June 23, 2022 – H.U. Group Holdings Inc., and its wholly-owned subsidiary Fujirebio Holdings, Inc., and ADx... Read more
